NCT05893654View on ClinicalTrials.gov

Melphalan Chemoreduction for Ocular Melanoma

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 1, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Uveal Melanoma
Interventions
DRUG

Melphalan Injection

7.5mg of melphalan injected via intra-arterial catheterization of the ophthalmic artery.

RADIATION

Plaque brachytherapy

Brachytherapy will be performed using a 24-mm notched plaque with Ruthenium-106 seeds.

Trial Locations (1)

14040-906

Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto - USP, Ribeirão Preto

All Listed Sponsors
collaborator

Fundação de Apoio ao Ensino, Pesquisa e Assistência do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo

OTHER

lead

Hospital das Clínicas de Ribeirão Preto

OTHER